TBX2 and breast neoplasm: Overall these data highlight a novel therapeutic opportunity whereby poor-prognosis, TBX2-overexpressing breast tumours may be pharmacologically exploited by targeting the CoREST-dependent gene repression network, to recover normal growth control.